Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)

  1. Jódar, E.
  2. Michelsen, M.
  3. Polonsky, W.
  4. Réa, R.
  5. Sandberg, A.
  6. Vilsbøll, T.
  7. Warren, M.
  8. Harring, S.
  9. Ziegler, U.
  10. Bain, S.
Journal:
Diabetes, Obesity and Metabolism

ISSN: 1463-1326,  1462-8902

Year of publication: 2020

Volume: 22

Issue: 8

Pages: 1339-1347

Type: Article

DOI: 10.1111/DOM.14039 GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus